Article
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Proceedings of the National Academy of Sciences of the United States of America - 21 Jul 2015
Phuchareon Janyaporn, McCormick Frank, Eisele David W, Tetsu Osamu
Abstract excerpt
Nonsmall cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. About 14% of NSCLCs harbor mutations in epidermal growth factor receptor (EGFR). Despite remarkable progress in treatment with tyrosine kinase inhibitors (TKIs), only 5% of patients achieve tumor reduction >90%. The limited primary responses are attributed partly to drug resistance inherent in the tumor cells before therapy begins....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.